希美加群：一篇悼词。 - Suppr

Suppr

超能文献

Ximelagatran: an eulogy.

作者信息

Boos Christopher J, Lip Gregory Y H

出版信息

Thromb Res. 2006;118(3):301-4. doi: 10.1016/j.thromres.2006.02.012. Epub 2006 Apr 19.

DOI:10.1016/j.thromres.2006.02.012

PMID:16626788

Abstract

摘要

相似文献

Ximelagatran: an eulogy.希美加群：一篇悼词。

Thromb Res. 2006;118(3):301-4. doi: 10.1016/j.thromres.2006.02.012. Epub 2006 Apr 19.

The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee.新药效益与风险分析的挑战：来自希美加群美国食品药品监督管理局心血管咨询委员会的经验教训

Contemp Clin Trials. 2006 Oct;27(5):432-40. doi: 10.1016/j.cct.2006.04.005.

Ximelagatran data fail to impress FDA.

Am J Health Syst Pharm. 2004 Dec 1;61(23):2472, 2474-5, 2480. doi: 10.1093/ajhp/61.23.2472.

How can 'Hy's law' help the clinician?“海氏法则”如何帮助临床医生？

Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):235-9. doi: 10.1002/pds.1210.

Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran.新型抗血栓药物的安全性评估：来自希美加群EXTEND研究的经验教训。

Thromb Res. 2009;123(3):488-97. doi: 10.1016/j.thromres.2008.02.017. Epub 2008 May 15.

Hy's law: predicting serious hepatotoxicity.海氏法则：预测严重肝毒性

Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):241-3. doi: 10.1002/pds.1211.

'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective.“海氏法则”、“曲格列酮规则”及其他严重药物性肝毒性的预测指标：权衡风险与获益

Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):221-9. doi: 10.1002/pds.1209.

Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.在使用希美加群进行静脉血栓栓塞症（VTE）长期二级预防期间，VTE复发或出血的预后因素。

Thromb Haemost. 2005 Sep;94(3):522-7.

Drug-induced liver injury in humans: the case of ximelagatran.人类药物性肝损伤：希美加群的案例

Handb Exp Pharmacol. 2010(196):407-18. doi: 10.1007/978-3-642-00663-0_13.

A better way to prevent blood clots? A drug derived from cobra venom offers an alternative to warfarin, although liver problems temper its benefits.

Harv Heart Lett. 2005 May;15(9):3.

引用本文的文献

Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.新型口服抗凝药与心房颤动及慢性心力衰竭的卒中预防

Heart Fail Rev. 2014 May;19(3):391-401. doi: 10.1007/s10741-013-9398-3. Epub 2013 Jun 25.

Target-specific oral anticoagulants in atrial fibrillation: results of phase III trials and comments on sub-analyses.心房颤动中靶向性口服抗凝剂：III 期临床试验结果及亚分析评论。

J Thromb Thrombolysis. 2013 Aug;36(2):155-62. doi: 10.1007/s11239-013-0925-9.

In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban.使用全球止血测定法进行的体外研究，以检查直接凝血酶抑制剂：达比加群和阿加曲班在血浆中的抗凝作用。

J Thromb Thrombolysis. 2013 Feb;35(2):131-9. doi: 10.1007/s11239-012-0791-x.

Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician.心房颤动的抗栓治疗：为临床医生翻译的指南

J Thromb Thrombolysis. 2008 Dec;26(3):167-74. doi: 10.1007/s11239-008-0272-4. Epub 2008 Sep 21.

Management of venous thromboembolism in the elderly.老年人静脉血栓栓塞的管理

Drugs Aging. 2006;23(8):651-71. doi: 10.2165/00002512-200623080-00003.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验